The Law Nigeria Already Has: Regulation 20 and a Question for the Agency
A law nobody enforces is still a law, and somebody is breaking it.
Claims that African jurisdictions impose no ingredient-labelling duty on menstrual products run through the advocacy literature, through trade commentary, and through the early drafting of this file. Checking the claim against primary sources dissolves it. Statutory Instrument No. 42 of 2024, printed in the Federal Republic of Nigeria Official Gazette No. 176, Volume 111, at Lagos on 16 October 2024, sets a labelling requirement for these products more demanding than New York’s, more demanding in one particular than California’s, and more demanding than anything the European Union imposes on a tampon. Error of this kind arises from assuming what African regulation looks like rather than reading it, and the assumption travels because almost nobody opens the Gazette.
Regulation 20 runs to less than a page. A complete list of composition or components shall appear on the primary and secondary label, in decreasing order of predominance. Where a product carries no secondary packaging, the list goes on the primary label. Components below one percent may be listed in any order after those at one percent or more. Declaration shall be prominent, readable and understandable under normal conditions of purchase. Subregulation seven, seventeen words long, is the provision that ought to settle the argument: where a composition or component is known to cause hypersensitivity, such shall be declared on the label.
Colophonium causes hypersensitivity. So does methyldibromo glutaronitrile, which the European Union removed from leave-on cosmetics after sensitization rates climbed through the 1990s. Both appear in the dermatological record as agents of vulvar dermatitis traced to sanitary pads, and both were named in Part 1. Clinically, the significance of subregulation seven lies in the nature of the process it addresses. Delayed hypersensitivity is a type IV immune reaction, mediated by memory T cells, and it does not resolve with time or avoidance. Once a woman is sensitized to rosin she will react to a rosin-bearing adhesive on every subsequent contact for the remainder of her life. Management consists of one intervention, which is identification of the allergen followed by avoidance, and avoidance is impossible without a label. Nigerian law has required that label since October 2024.
Pads fall inside these Regulations through a classification decision most Nigerians would find surprising. NAFDAC registers sanitary pads as medical devices, alongside diaper pants and toothbrushes, and does so in practice rather than on paper; agency records carry ninety-four registered sanitary pad entries among more than a thousand device registrations, on a five-year renewal cycle. Regulation 47 prohibits manufacture, importation, distribution, sale or display for sale of any device not labelled in accordance with the Regulations. Nothing in the text carves out consumer hygiene goods.
Penalties reach individuals as well as companies. Conviction under Regulation 48 exposes a person to imprisonment up to one year, a fine up to eight hundred thousand naira, or both, and a body corporate to five million naira. Subregulation two extends liability to directors, managers, secretaries, partners and trustees, reversing the ordinary burden by requiring each of them to prove the offense occurred without their knowledge, consent or connivance. Drafting of that severity does not happen by accident.
Comparison with the jurisdictions usually held up as leaders is instructive. Menstrual products are not medical devices anywhere in the European Union, because the Medical Devices Regulation requires a medical purpose and menstruation is not a disease. Pads and tampons sit instead under general consumer product law, currently the General Product Safety Regulation in force since December 2024. Asked directly whether producers must disclose what a tampon contains, the European Commission answered that the governing instrument imposes no such obligation and requires only adequate warnings. British products fall under equivalent domestic regulations with a voluntary industry code addressing toxic shock.
American federal law reaches no further than Europe’s. Menstrual products are Class II devices, ingredient labelling is not required, and a Menstrual Products Right to Know Act has been introduced in Congress repeatedly since 2019 without passing. New York legislated at state level in October 2019, adding section 399-aaaa to its General Business Law and requiring disclosure of every intentionally added substance, with penalties running to one percent of a manufacturer’s annual in-state sales. California followed in September 2020, requiring all ingredients by weight in order of predominance, on the label and on the manufacturer’s website, for products manufactured on or after 1 January 2023.
Set the operative language side by side rather than the reputations. New York reaches intentionally added substances, which leaves out whatever arrived by another route. California permits a manufacturer holding a trade secret to disclose by common name. Nigerian Regulation 20 requires a complete list of composition or components, contains no trade-secret provision anywhere in its text, and adds a hypersensitivity clause neither American statute carries. On the page, Nigeria holds the strictest menstrual product labelling law of the four.
One further provision closes the circle, and it cuts against what a reader might expect. Composition data does reach NAFDAC, through the certificate of analysis and label vetting that registration requires. Regulation 7 then forbids disclosure of information supplied by an applicant, save with written consent, on the Agency’s direction, or in proceedings. Full composition therefore rests in a file in Abuja under a confidentiality rule, leaving the printed label as the sole lawful channel by which any of it reaches the woman buying the product. Remove Regulation 20 and nothing remains.
Precision about what has been established matters here more than emphasis. Existence of the law is documented, from the Gazette rather than from a summary of it. Compliance is not. No source consulted for this part establishes whether a single pack of sanitary pads on sale in Aba, Onitsha, Kano or Lagos today carries a Regulation 20 composition list. Settling that requires buying product, photographing packs, recording batch numbers and registration numbers, and publishing the exhibits, and until that work is complete this file asserts nothing about compliance.
Restraint of that kind protects the remainder of the volume. A manufacturer accused of breaching Regulation 20 by a publication that never examined its packaging has a defense that writes itself, and the accusation would carry the documented material in Parts 1, 2, 4 and 5 down with it. Physical verification is scheduled.
Grounds for suspicion remain structural rather than speculative. Nigerian pad supply runs on imports and regional contract manufacture, and a brand name printed on a wrapper in Lagos guarantees nothing about the specification behind it. More immediately, a substantial share of product reaches women from open trays, sold singly or in threes with the wrapper already discarded. Regulation 20 governs a label. It says nothing about a tray.
Objections deserve their strongest form. Regulations made in October 2024 are recent, manufacturers require lead time to redesign artwork, and neither American state expected overnight compliance; New York allowed eighteen months and California set a manufacturing date more than two years forward. Nigerian Regulations as published carry no comparable transition provision, which arguably renders immediate compliance an unreasonable expectation rather than a legal certainty. Enforcement across a market of two hundred million people, much of it informal, strains any agency. And NAFDAC has pursued substantial enforcement across several regulated categories in recent years, which is not the record of a body indifferent to its own rules.
Each of those points carries weight, and none touches the finding. Argument in Nigeria has moved ground. Persuading a legislature is no longer necessary, because the legislature acted and the Minister signed. Drafting model language is no longer necessary, because Regulation 20 sits in the Gazette with penalties attached and personal liability for company officers. What remains is a compliance question with a determinate answer, which places a woman presenting with vulvar dermatitis in a considerably better position than this file believed her to occupy.
For any company supplying both markets, a consequence follows. A pad sold in Sacramento carries its ingredients because California requires them. A pad sold in Nigeria is required by Nigerian law to carry a complete composition list with any known sensitizer declared. Where the same manufacturer supplies both and the packs differ, the discrepancy is not a commercial judgment about market expectations but a matter for the Agency that wrote Regulation 20.
Right of reply in this part goes to NAFDAC, and three questions are put on the record. How many of the ninety-four registered sanitary pad products currently carry a Regulation 20 composition list on the retail pack? What transition period, if any, followed 16 October 2024? What enforcement action under Regulation 48 has been taken in this category to date? Any answer will be published in full alongside this text.
Forensic Exhibit Plate / Plate.1 — Regulation 20
Plate 3.1 — Regulation 20
Statutory exhibit reproducing the operative subregulations of S.I. No. 42 of 2024, with the sensitizers documented in Part 1 set against the hypersensitivity clause at 20(7).
Evidence Class: Documented — Primary Statutory Text
Forensic Exhibit Plate / Plate.2 — Four Jurisdictions
Plate 3.2 — Four Jurisdictions
Comparative matrix of what Nigerian, New York, Californian and European Union law each require a menstrual product package to disclose.
Evidence Class: Documented — Statutory Comparison
Forensic Exhibit Plate / Diagram 3.3 The Surface The Statute Governs
Diagram 3.3 — The Surface the Statute Governs
Clinical schematic of the contact zones an external product meets, and the barrier properties of each.
Evidence Class: Clinical Schematic — Documented Tissue Properties
Source & Clinical Standards
Note: The chemistry, clinical findings, regulatory benchmarks and analytical figures throughout this series are drawn directly from peer-reviewed medical and toxicological literature, independent laboratory analysis, published case reports and established regulatory frameworks. Anatomical plates are reference schematics prepared from the published descriptive literature and are not to scale. To protect the narrative rhythm of this layout, the individual bibliographies carried by each part have been unified.
A complete master registry—cataloging all underlying source literature, analytical studies, case reports, patent disclosures and institutional frameworks (including the World Health Organization, the United States Food and Drug Administration’s medical-device classification of menstrual products, European Union restrictions on leave-on biocides, the New York State menstrual-product disclosure law, and the standing NAFDAC position)—is compiled in full at the conclusion of the complete volume.
Every claim in this series is carried as documented, alleged or inferred, and no finding of criminal guilt is made against any individual. A standing right of reply is held open for every named party.
